Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | BiTEs for MM

Yu-Tzu Tai • 15 Sep 2019
IMW 2019
Multiple Myeloma Antibodies

Dr. Yu-Tzu Tai, PhD- of the Dana-Farber Cancer Institute, Boston, MA, describes the success of bi-specific T-cell engagers (BiTEs) in the clinical setting at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Yu-Tzu Tai

3:28
Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
5:22
Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
1:35
Rationale for using immunotherapies in the frontline treatment of multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
3:09
Reducing CAR-T toxicity
Yu-Tzu Tai • 15 Sep 2019

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals